Considerando che ormai questo blog riceve molte visite di persone interessate al CRM197 ( immagino purtroppo siano direttamente malati di cancro o loro familiari ) , mi permetto di linkare gli sviluppi di alcune recenti ricerche provenienti dal Giappone che proseguono lungo la strada tracciata dal Dott. Silvio Buzzi.
Basta una minima conoscenza dell'inglese per intuire che gli esiti sono molto promettenti ( peccato che nessun media italiano ne parli dal 2011 ) :
Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer [ ..] HB-EGF expression in HSC3 and SAS cells treated with CRM197 was
significantly reduced and cell proliferation was inhibited. The
invasiveness of CRM197-treated cells was relatively low. MMP-9 and VEGF
were suppressed in HSC3 treated with CRM197 on zymography and Western
blot. Further, tumor growth in xenografted mice was suppressed by CRM197
or CDDP at 1 mg/kg/day. Also, the coadministration of CDDP and CRM197
at 1 mg/kg/day completely inhibited tumor formation. These results
suggest that HB-EGF is a target for oral cancer and that CRM197 is
effective in oral cancer therapy. [..]
[..] We observed that CRM197 significantly induced anti-proliferative activity in a dose-dependent manner with the cell-cycle arrest at the G0/G1 phase and enhanced apoptosis in A2780/Taxol and A2780/CDDP cells. The sensitive ovarian carcinoma parental cell line (A2780), A2780/Taxol and A2780/CDDP cells formed tumors in nude mice, and enhanced tumorigenicity was observed in drug-resistant tumors. Furthermore, we observed that CRM197 significantly suppressed the growth of drug-resistant ovarian cancer xenografts in vivo (p < 0.001). These results suggest that CRM197 as an HB-EGF-targeted agent has potent anti-tumor activity in paclitaxel- and cisplatin-resistant ovarian cancer which over-express HB-EGF. [..]
[..] The effects of growth inhibition and apoptosis were markedly enhanced
after a combination of cisplatin with CRM197 plus the PI3K inhibitor
LY294002 or wortmannin. Therefore, CRM197 combined with cisplatin could
enhance growth inhibition and apoptosis of glioma cells by inhibiting
the cisplatin-induced PI3K/Akt pathway. [..]
To be continued , nella speranza che i media italiani facciano finalmente il loro dovere .
